» Articles » PMID: 32191753

Diagnostic and Health Service Pathways to Diagnosis of Cancer-registry Notified Cancer of Unknown Primary Site (CUP)

Overview
Journal PLoS One
Date 2020 Mar 20
PMID 32191753
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer of unknown primary (CUP) is a late-stage malignancy with poor prognosis, but we know little about what diagnostic tests and procedures people with CUP receive prior to diagnosis. The purpose of this study was to determine how health service utilisation prior to diagnosis for people with cancer-registry notified CUP differs from those notified with metastatic cancer of known primary.

Methods: We identified people with a cancer registry notification of CUP (n = 327) from the 45 and Up Study, a prospective cohort of 266,724 people ≥45 years in New South Wales, Australia, matched with up to three controls with a diagnosis of metastatic cancer of known primary (n = 977). Baseline questionnaire data were linked to population health data to identify all health service use, diagnostic tests, and procedures in the month of diagnosis and 3 months prior. We used conditional logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

Results: After adjusting for age and educational attainment, people with a cancer-registry notified CUP diagnosis were more likely to be an aged care resident (OR = 2.78, 95%CI 1.37-5.63), have an emergency department visit (OR = 1.65, 95%CI 1.23-2.21), serum tumor marker tests (OR = 1.51, 95%CI 1.12-2.04), or a cytology test without immunohistochemistry (OR = 2.01, 95%CI 1.47-2.76), and less likely to have a histopathology test without immunohistochemistry (OR = 0.43, 95%CI 0.31-0.59). Neither general practitioner, specialist, allied health practitioner or nurse consultations, hospitalisations, nor imaging procedures were associated with a CUP diagnosis.

Conclusions: The health service and diagnostic pathway to diagnosis differs markedly for people notified with CUP compared to those with metastatic cancer of known primary. While these differences may indicate missed opportunities for earlier detection and appropriate management, for some patients they may be clinically appropriate.

Citing Articles

Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin.

Ugalde A, Tothill R, Quinn S, Wong H, Prall O, Mitchell C BMC Cancer. 2025; 25(1):171.

PMID: 39881222 PMC: 11776227. DOI: 10.1186/s12885-025-13506-4.


Patient characteristics associated with definitive diagnosis of metastatic pancreatic cancer in those initially diagnosed with cancer of unknown primary.

Lee White L, Smith-Gagen J, Elliott L, Lu M Mol Clin Oncol. 2023; 19(6):101.

PMID: 38022848 PMC: 10666077. DOI: 10.3892/mco.2023.2697.


Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia.

Gordon L, Wood C, Tothill R, Webb P, Schofield P, Mileshkin L Pharmacoecon Open. 2022; 7(1):111-120.

PMID: 36253664 PMC: 9929003. DOI: 10.1007/s41669-022-00371-1.


Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice.

Mileshkin L, Bochtler T, Gatta G, Kurzrock R, Beringer A, Muller-Ohldach M Cancers (Basel). 2022; 14(12).

PMID: 35740574 PMC: 9221531. DOI: 10.3390/cancers14122905.


Prediction of Survival Prognosis for Spinal Metastasis From Cancer of Unknown Primary: Derivation and Validation of a Nomogram Model.

Yang M, Ma X, Wang P, Yang J, Zhong N, Liu Y Global Spine J. 2022; 14(1):283-294.

PMID: 35615968 PMC: 10676151. DOI: 10.1177/21925682221103833.

References
1.
Mnatsakanyan E, Tung W, Caine B, Smith-Gagen J . Cancer of unknown primary: time trends in incidence, United States. Cancer Causes Control. 2014; 25(6):747-57. DOI: 10.1007/s10552-014-0378-2. View

2.
Trevena J, Rogers K, Jorm L, Churches T, Armstrong B . Quantifying under-reporting of pathology tests in Medical Benefits Schedule claims data. Aust Health Rev. 2013; 37(5):649-53. DOI: 10.1071/AH13092. View

3.
Richardson D . An incidence density sampling program for nested case-control analyses. Occup Environ Med. 2004; 61(12):e59. PMC: 1740694. DOI: 10.1136/oem.2004.014472. View

4.
Pavlidis N, Pentheroudakis G . Cancer of unknown primary site. Lancet. 2012; 379(9824):1428-35. DOI: 10.1016/S0140-6736(11)61178-1. View

5.
Vajdic C, Perez-Concha O, Dobbins T, Ward R, Schaffer A, van Leeuwen M . Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP). Cancer Epidemiol. 2019; 60:156-161. DOI: 10.1016/j.canep.2019.04.004. View